Page 7,094«..1020..7,0937,0947,0957,096..7,1007,110..»

Drugs & Bugs: A New App from Monthly Prescribing Reference

Posted: Published on February 24th, 2012

NEW YORK, Feb. 23, 2012 /PRNewswire/ -- Monthly Prescribing Reference (MPR) is pleased to announce the launch of the Drugs & Bugs App, an essential resource for healthcare professionals. The app provides comprehensive information on antibiotic spectrum of efficacy against microorganisms. Clinicians may use the searchable alpha indices or search drugs and bugs by bacterial class or pharmacological class to begin their query. The Drugs & Bugs App features: A database of more than 100 antibiotics and nearly 200 bacterial pathogens Smart Search capability by pathogen, type of infection, brand and generic drug names Quick-to-read results on spectrum of activity Comprehensive drug monographs for anti-infective agents Useful comparative charts by drug class Clinical calculators Drugs & Bugs was developed by MPR and US Biomedical Information Systems (USBMIS), MPR's app development partner, in cooperation with Philip Chung, PharmD, BCPS; Clinical Pharmacy Manager in Infectious Diseases at Montefiore Medical Center, NY. The drug monographs are frequently updated and reviewed by MPR's team of pharmacists and physicians. "Choosing an empiric antibiotic regimen can be daunting," said Dr. Chung. "The Drugs & Bugs App is a useful tool for selecting empiric antibiotic regimens before susceptibility results become available. The app also aids clinicians in the … Continue reading →

Posted in Drugs | Comments Off on Drugs & Bugs: A New App from Monthly Prescribing Reference

Online and Mail-Order Pharmacies: How to Be Safe

Posted: Published on February 24th, 2012

By Joanne Barker WebMD Feature People get deals on shoes, travel, and appliances online. Why not prescription drugs? You can find lower prices and convenience through mail-order or online pharmacies. Just be careful. "Rogue" pharmacies use the Internet to market counterfeit drugs. You could end up with something that doesn’t treat your condition and could harm your health. Recommended Related to Healthy Seniors 4 Ways to Stop Age-Related Memory Loss She could deal with constantly forgetting her shopping list, and she'd made a habit of writing down where she'd parked her car, each and every time. But in her mid-50s, Janis Mara's memory problems started costing her money. Late fees began piling up because she forgot to pay her bills. "Over time, it really intensified," she says. "I wanted to think I was just getting older, but my fear was that it was Alzheimer's." After bugging her HMO for an MRI, Mara discovered that her lapses weren't anything... Read the 4 Ways to Stop Age-Related Memory Loss article > > In this article, WebMD helps you find the real deals at mail-order and online pharmacies.   Mail-Order Pharmacies = Convenience and Lower Costs Many insurers and some retail pharmacies now … Continue reading →

Posted in Online Pharmacy | Comments Off on Online and Mail-Order Pharmacies: How to Be Safe

Specialty Pharmacy News Obtains Exclusive Data on the Effectiveness of Two Hepatitis C Drugs

Posted: Published on February 24th, 2012

Clinical trials conducted by Burman's Specialty Pharmacy found Incivek and Victrelis to hold much more promise than the previous regimen did of treating Hepatitis C, according to research exclusively shared with Atlantic Information Services's Specialty Pharmacy News. Washington, DC (PRWEB) February 24, 2012 One specialty pharmacy’s real-world data for two drugs approved in 2011 for the treatment of hepatitis C support clinical trials data showing that the new therapies hold much more promise than the previous regimen did of clearing the virus, Atlantic Information Services's Specialty Pharmacy News has learned. The drugs, Incivek and Victrelis, also could cut the current 48-week treatment time down to 24 weeks for certain patients if they achieve an early viral response. With patients who were among the first to be dosed recently hitting the 24-week mark in their regimens, Burman’s Specialty Pharmacy has shared exclusive data with Specialty Pharmacy News on what it has seen so far among about 700 people it has treated with Merck & Co., Inc.’s Victrelis and Vertex Pharmaceuticals Inc.’s Incivek. Within the patient population naïve to previous hepatitis C treatment, 66% on Victrelis achieved an early viral response. Similarly, among a sample of 77 patients taking Incivek, 75% of … Continue reading →

Posted in Pharmacy | Comments Off on Specialty Pharmacy News Obtains Exclusive Data on the Effectiveness of Two Hepatitis C Drugs

Pharmacy director to receive top honor for patient safety, smart clinical practices

Posted: Published on February 24th, 2012

Public release date: 22-Feb-2012 [ | E-mail | Share ] Contact: Duke Helfand duke.helfand@cshs.org 310-248-6608 Cedars-Sinai Medical Center Los Angeles, Feb. 23, 2012 -- During her 34-year career, Rita Shane, PharmD, has earned a reputation as a tireless advocate for patient safety ? one who has transformed the way pharmacists perform their jobs. Now that work has brought Shane, director of pharmacy services at Cedars-Sinai Medical Center, the highest honor for health system pharmacists. She is the recipient of the 2012 Harvey A.K. Whitney Lecture Award. In choosing Shane, the American Society of Health-System Pharmacists cited her commitment to safety and her efforts to expand clinical pharmacy services at Cedars-Sinai. The organization pointed out that Shane has led the creation of a "progressive pharmacy practice model" while at the helm of Cedars-Sinai's pharmacy operation, training pharmacists how to deliver specialized services for patients with diverse medical needs, whether in the Emergency Department, transplant units or other settings. The pharmacist group also mentioned Shane's role as an advocate for regulatory changes in California that allow pharmacy technicians to check each other's work in acute care settings, freeing pharmacists from paperwork to spend more time with patients. "Rita is an exceptional leader, … Continue reading →

Posted in Pharmacy | Comments Off on Pharmacy director to receive top honor for patient safety, smart clinical practices

ISSCR Honors Stem Cell Research Pioneer with Prestigious McEwen Award for Innovation

Posted: Published on February 24th, 2012

Newswise — The International Society for Stem Cell Research (ISSCR) is pleased to announce the winner of the 2012 McEwen Award for Innovation, a coveted prize in the field of stem cell research and regenerative medicine. The 2012 recipient is Rudolf Jaenisch, MD, Founding Member of the Whitehead Institute for Biomedical Research and Professor of Biology at the Massachusetts Institute of Technology in recognition of his pioneering discoveries in the areas of genetic and epigenetic control of development in mice that directly impact the future potential of embryonic stem cells and induced pluripotent stem cells for therapeutic utility. The McEwen Award for Innovation is supported by the McEwen Centre for Regenerative Medicine in Toronto, Ontario, Canada. The $100,000 award honors original thinking and groundbreaking research pertaining to stem cells or regenerative medicine that opens new avenues of exploration towards the understanding or treatment of human disease or affliction. “Rudolf Jaenisch has consistently contributed new and groundbreaking discoveries to stem cell biology and regenerative medicines that have changed the way stem cell research is conducted, said Fred H. Gage, PhD, ISSCR President. “Importantly, Rudolf not only has an uncanny sense of the next big question, but also conducts his experiments with … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on ISSCR Honors Stem Cell Research Pioneer with Prestigious McEwen Award for Innovation

AVI BioPharma Announces Fourth Quarter and Full Year 2011 Financial Results and Corporate Update Conference Call

Posted: Published on February 23rd, 2012

BOTHELL, WA--(Marketwire -02/23/12)- AVI BioPharma, Inc. (NASDAQ: AVII - News), a developer of RNA-based therapeutics, will report fourth quarter and full year 2011 financial results after the NASDAQ Global Market closes on Thursday, March 1, 2012. Subsequently, at 5:00 p.m., Eastern Time (2:00 p.m., Pacific Time), Chris Garabedian, AVI's president and CEO, will host a conference call to discuss fourth quarter and full year 2011 financial results and to provide a corporate update. The conference call may be accessed by dialing 866.510.0676 for domestic callers and 617.597.5361 for international callers. The passcode for the call is 79552457. Please specify to the operator that you would like to join the "AVI BioPharma fourth quarter and full year 2011 earnings call." The conference call will be webcast live under the events section of AVI's website at http://www.avibio.com and will be archived there following the call for 90 days. Please connect to AVI's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary. About AVI BioPharma AVI BioPharma is focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on AVI BioPharma Announces Fourth Quarter and Full Year 2011 Financial Results and Corporate Update Conference Call

All mental health disorders should get insurance coverage, not just autism, coalition says

Posted: Published on February 23rd, 2012

LANSING -- Legislation that would require insurers to cover autism treatments unfairly singles out one condition, says a coalition that wants coverage for all mental health issues. Gov. Rick Snyder, who backs the autism legislation, and lawmakers are being urged today to adopt a state law that would improve insurance coverage for all neuropsychiatric disorders, including mental illness, addiction, autism and developmental disorders. “Autism certainly ought to be covered. That’s not the argument,” said Michael Reagan, external relations officer of Cherry Street Health Services in Grand Rapids. “There are other neuropsychiatric disorders that can be just as debilitating and cause just as much of a problem as autism.” “The governor and Senate leaders have announced a course that is discriminatory, stigmatizing, and problematic for the state,” said Mark Reinstein, president of the Mental Health Association in Michigan. He said the coalition supports a bill introduced by state Sen. Rebekah Warren, D-Ann Arbor, which assures equal coverage for all neuropsychiatric disorders when employers choose to include behavioral health coverage in their policies. Michigan is one of only seven states that does not have parity legislation requiring insurers to provide the same coverage for mental disorders as for physical illness, says Michigan … Continue reading →

Comments Off on All mental health disorders should get insurance coverage, not just autism, coalition says

Deep Brain Stimulation Treatment Reduces Tremors from Parkinson’s Disease – Video

Posted: Published on February 23rd, 2012

22-02-2012 09:48 See how deep brain stimulation reduced the tremors a patient had from Parkinson's disease. Learn more at http://www.exempla.org/dbs View original post here: Deep Brain Stimulation Treatment Reduces Tremors from Parkinson's Disease - Video … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Deep Brain Stimulation Treatment Reduces Tremors from Parkinson’s Disease – Video

FDA Accepts Impax Pharmaceuticals NDA Filing for IPX066 for the Treatment of Idiopathic Parkinson’s Disease

Posted: Published on February 23rd, 2012

HAYWARD, Calif.--(BUSINESS WIRE)-- Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. (NASDAQ: IPXL - News) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for IPX066 for the treatment of idiopathic Parkinson’s disease (PD) submitted to the Agency on December 21, 2011. IPX066 is a patented extended release capsule formulation of carbidopa-levodopa (CD-LD). The Prescription Drug User Fee Date (PDUFA) for a decision by the FDA is October 21, 2012. IPX066 has been licensed to GlaxoSmithKline (GSK) for countries outside the U.S. and Taiwan for development and marketing. IPX066 has undergone extensive clinical development, including multiple studies in early and advanced PD in the U.S. and in Europe. The NDA included data from three controlled Phase III studies and two open label extensions of IPX066 in both early and advanced PD. IPX066 has been investigated in more than 1,000 subjects. About IPX066 IPX066 is an investigational extended release capsule formulation of CD-LD which is intended to maintain consistent plasma concentration of levodopa for a longer duration versus immediate release levodopa, which may have an impact on fluctuations in clinical response. It is not approved or licensed anywhere … Continue reading →

Posted in Parkinson's Treatment | Comments Off on FDA Accepts Impax Pharmaceuticals NDA Filing for IPX066 for the Treatment of Idiopathic Parkinson’s Disease

Genzyme Announces EMA Accepts Oral Teriflunomide Marketing Application for Treatment of Multiple Sclerosis

Posted: Published on February 23rd, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today the European Medicines Agency (EMA) has accepted the filing of the marketing authorization application (MAA) for once-daily oral teriflunomide for the treatment of relapsing forms of multiple sclerosis (MS). Acceptance of the MAA starts the EMA’s review process. “The filing represents another important milestone for teriflunomide and brings us one step closer to offering a new treatment option to patients with relapsing MS,” said Bill Sibold, Senior Vice President, Head of Multiple Sclerosis, Genzyme. “As an oral therapy with a promising clinical profile, teriflunomide is extremely well positioned to provide an alternative therapeutic option to patients who are currently taking injectable therapies. Those injectable therapies make up approximately 80 percent of the MS market today.” The purpose of the MAA is to secure approval to market and allow prescription of teriflunomide in the European Union based on data from two completed pivotal Phase III trials, TEMSO and TENERE. These trials represent two of five efficacy studies of teriflunomide in MS that are completed or underway, making the clinical program one of the largest and broadest of any MS therapy in development. An application to market teriflunomide in … Continue reading →

Posted in MS Treatment | Comments Off on Genzyme Announces EMA Accepts Oral Teriflunomide Marketing Application for Treatment of Multiple Sclerosis

Page 7,094«..1020..7,0937,0947,0957,096..7,1007,110..»